HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics …

1 day ago · Shares of YMAB opened at $6.33 on Monday. The company has a market capitalization of $283.51 million, a P/E ratio of -11.72 and a beta of 0.69. Y-mAbs Therapeutics …

$6.33
OFF

HC Wainwright Reaffirms Buy Rating For Y-mAbs Therapeutics …

2 weeks from now

1 day ago · Shares of YMAB opened at $6.33 on Monday. The company has a market capitalization of $283.51 million, a P/E ratio of -11.72 and a beta of 0.69. Y-mAbs Therapeutics …

etfdailynews.com

$22.00
OFF

Y-Mabs Therapeutics (YMAB) Receives A Buy From H.C. Wainwright

2 weeks from now

3 days ago · H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) on January 10 and set a price target of $22.00. The …

businessinsider.com

$9.77
OFF

HC Wainwright Reaffirms “Buy” Rating For Y-mAbs Therapeutics …

2 weeks from now

Dec 13, 2024 · YMAB opened at $9.77 on Wednesday. The firm has a market cap of $437.60 million, a P/E ratio of -18.09 and a beta of 0.61. Y-mAbs Therapeutics has a 1-year low of …

etfdailynews.com

$7.39
OFF

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus …

2 weeks from now

6 days ago · Y-mAbs Therapeutics stock opened at $7.39 on Friday. Y-mAbs Therapeutics has a 52 week low of $6.92 and a 52 week high of $20.90. The firm has a market cap of $330.99 …

etfdailynews.com

$22.00
OFF

Y-mAbs: Strategic Partnership And Strong Financial Outlook …

2 weeks from now

Nov 15, 2024 · Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report).The associated price target is $22.00. Robert …

businessinsider.com

$22.00
OFF

Navigating 8 Analyst Ratings For Y-mAbs Therapeutics

2 weeks from now

Sep 9, 2024 · Y-mAbs Therapeutics (NASDAQ:YMAB) ... Navigating 8 Analyst Ratings For Y-mAbs Therapeutics ... HC Wainwright & Co. Maintains: Buy: $22.00: $22.00: Etzer Darout:

nasdaq.com

$23.00
OFF

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus ...

2 weeks from now

Dec 16, 2024 · A number of analysts have issued reports on the stock. Wedbush reissued an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a …

marketbeat.com

$26.00
OFF

Y-Mabs Therapeutics: Promising Pipeline Developments And …

2 weeks from now

Nov 11, 2024 · Canaccord Genuity analyst John Newman maintained a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) on November 8 and set a price target of $26.00.. …

businessinsider.com

93%
OFF

Y-mabs Therapeutics. Stock Price Forecast. Should You Buy YMAB?

2 weeks from now

Jan 8, 2025 · Sell candidate since Nov 12, 2024 Loss -43.93%. The Y-mAbs Therapeutics Inc. stock price fell by -3.40% on the last day (Wednesday, 8th Jan 2025) from $7.65 to $7.39.It …

stockinvest.us

$6.89
OFF

Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reiterated At …

2 weeks from now

3 days ago · NASDAQ:YMAB opened at $6.89 on Friday. The firm’s 50 day simple moving average is $10.32 and its 200 day simple moving average is $12.13. Y-mAbs Therapeutics …

etfdailynews.com

$6.50
OFF

North Bergen Njtransit Park And Ride. : R/newjersey - Reddit

2 weeks from now

Think of it like a combined price of $6.50 bus RT + $3.50 parking. I guess you could buy your ticket separately, but then you’re just wasting the printed ticket that comes with lot entry. …

reddit.com

$6.33
OFF

Barclays PLC Raises Holdings In Y-mAbs Therapeutics, Inc.

2 weeks from now

1 day ago · Y-mAbs Therapeutics Price Performance. Shares of YMAB stock opened at $6.33 on Wednesday. The business’s fifty day moving average price is $10.15 and its 200 day moving …

etfdailynews.com

FAQs about HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics … Coupon?

Should you buy y-mAbs Therapeutics (y-mAbs)?

Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. Finally, HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. ...

Will HC Wainwright reissue a 'Buy' rating on Y-mAbs Therapeutics?

HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. ...

Who owns y-mAbs Therapeutics?

SG Americas Securities LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Institutional investors own 70.85% of the company’s stock. (Get Free Report) ...

How do I receive news & ratings for Y-mAbs Therapeutics?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

Will y-mAbs Therapeutics (ymab) post -0.66 EPs?

On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year. A number of large investors have recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $44,000. ...

Are hedge funds buying ymab?

Several hedge funds have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $44,000. ...